Antibodies News and Research

RSS

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

New evidence shows how personality affects health and wellbeing

Researchers have found new evidence that explains how some aspects of our personality may affect our health and wellbeing, supporting long-observed associations between aspects of human character, physical health and longevity.

12 Dec 2014

Research finding could lead to development of effective vaccines against microbial infections

The diverse functions of a special cell-recognition lipoprotein, LOX-1, weren't always fully understood. However, Baylor Research Institute investigators gained better insight into LOX-1's role in immune responses through a study recently published in Immunity. Investigators found that the lipoprotein promotes humoral responses, which could allow researchers to design effective vaccines against microbial infections, including influenza viruses and HIV.

11 Dec 2014

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

PAH markers identified among Chinese systemic sclerosis patients

A study of Chinese patients with systemic sclerosis has identified predictive markers for accompanying pulmonary arterial hypertension similar to those that have been identified in other ethnic groups.

9 Dec 2014

$Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors$

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors.

9 Dec 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

Study shows seasonal flu vaccines may protect individuals against many different viruses

Seasonal flu vaccines may protect individuals not only against the strains of flu they contain but also against many additional types, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology.

9 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment.

From Novo Nordisk 7 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

7 Dec 2014

Comb-shaped polymers efficiently protect proteins in vivo

An enzyme that usually triggers strong allergic reactions now circulates in the veins of a group of mice without alerting the immune system. As INRS Énergie Matériaux Télécommunications Research Centre Professor Marc A. Gauthier explains in an article published in the journal Nature Communications, a polymer was used to camouflage the enzyme before it was injected into the rodents. This was achieved by coating the enzyme to avoid an immune response in a manner that does not compromise its activity.

6 Dec 2014

Scientists undertake multiple strategies to tame Ebola virus

The Ebola epidemic in West Africa has pushed the decades-long search for a treatment to a frenetic pace. Somewhere in the virus' deceptively simple structure is a key to taming it. To find that key, scientists are undertaking multiple strategies, some of which are being fast-tracked for human testing, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.

4 Dec 2014

New technology reveals cellular gene transcription process in detail

A new technology that reveals cellular gene transcription in greater detail has been developed by Dr. Daniel Kaufmann of the University of Montreal Hospital Research Centre and the research team he directed. "This new research tool offers us a more profound view of the immune responses that are involved in a range of diseases, such as HIV infection. At the level of gene transcription, this had been difficult, complex and costly to do with current technologies, such as microscopy," explained the University of Montreal professor.

4 Dec 2014

New blood test could help detect cold-related asthma risk

People who have asthma generally suffer worse with colds caused by rhinoviruses than other people do. There are also asthmatics and patients with the severe lung condition COPD in whom the cold virus can trigger serious flare-ups of their condition. A team of researchers from the Institute of Pathophysiology and Allergy Research at the MedUni Vienna has now discovered how this risk group can be filtered out using a blood test.

2 Dec 2014

Antibodies News and Research

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

New evidence shows how personality affects health and wellbeing

Research finding could lead to development of effective vaccines against microbial infections

PD-L1 expression tied to favourable prognosis in SCLC

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

PAH markers identified among Chinese systemic sclerosis patients

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Study shows seasonal flu vaccines may protect individuals against many different viruses

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Researchers identify new targets for future CLL therapies

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Study: Key protein may help prevent tumor growth, promote wound healing

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

Comb-shaped polymers efficiently protect proteins in vivo

Scientists undertake multiple strategies to tame Ebola virus

New technology reveals cellular gene transcription process in detail

New blood test could help detect cold-related asthma risk

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo